Diamond Biotechnology Co., Ltd (TPEX:6815)
Taiwan · Delayed Price · Currency is TWD 31.60
-1.00 (-3.07%)
May 29, 2026, 1:54 PM CST
Diamond Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 501.49 | 768.25 | 616.1 | 434.84 | 395.2 | |
Revenue Growth (YoY) | -34.72% | 24.70% | 41.68% | 10.03% | 28.99% |
Cost of Revenue | 346.25 | 437.54 | 326.5 | 250.53 | 207.32 |
Gross Profit | 155.25 | 330.71 | 289.59 | 184.32 | 187.88 |
Selling, General & Admin | 181.95 | 176.56 | 194.89 | 111.31 | 111.86 |
Research & Development | 47.49 | 41.4 | 29.33 | 25.94 | 27.93 |
Operating Expenses | 241.17 | 222.4 | 225.69 | 138.1 | 140 |
Operating Income | -85.93 | 108.31 | 63.91 | 46.22 | 47.88 |
Interest Expense | -5.19 | -7.44 | -7.52 | -3.74 | -2.27 |
Interest & Investment Income | 2.28 | 1.89 | 0.7 | 0.43 | 0.04 |
Currency Exchange Gain (Loss) | - | 0.33 | 0.08 | -0.35 | 0.06 |
Other Non Operating Income (Expenses) | 8.99 | -2.68 | 1.17 | -0.83 | 2.86 |
EBT Excluding Unusual Items | -79.84 | 100.4 | 58.33 | 41.73 | 48.57 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.03 |
Gain (Loss) on Sale of Assets | - | -4.72 | - | 0.1 | 1.35 |
Other Unusual Items | - | - | - | - | 2.11 |
Pretax Income | -79.84 | 95.69 | 58.33 | 41.82 | 52.05 |
Income Tax Expense | -9.53 | 22.49 | 11.59 | 8.44 | 10.13 |
Net Income | -70.31 | 73.2 | 46.74 | 33.39 | 41.92 |
Net Income to Common | -70.31 | 73.2 | 46.74 | 33.39 | 41.92 |
Net Income Growth | - | 56.61% | 39.98% | -20.35% | 279.40% |
Shares Outstanding (Basic) | 40 | 38 | 37 | 36 | 36 |
Shares Outstanding (Diluted) | 40 | 39 | 37 | 36 | 36 |
Shares Change (YoY) | 2.60% | 4.92% | 1.02% | -0.00% | 3.35% |
EPS (Basic) | -1.78 | 1.90 | 1.27 | 0.92 | 1.15 |
EPS (Diluted) | -1.78 | 1.90 | 1.27 | 0.92 | 1.15 |
EPS Growth | - | 49.29% | 39.10% | -20.60% | 269.48% |
Free Cash Flow | -2.9 | 4.44 | -155.72 | 84.57 | -19.25 |
Free Cash Flow Per Share | -0.07 | 0.12 | -4.24 | 2.33 | -0.53 |
Dividend Per Share | - | 0.166 | 0.136 | 0.083 | 0.105 |
Dividend Growth | - | 22.01% | 63.63% | -20.67% | 283.21% |
Gross Margin | 30.96% | 43.05% | 47.01% | 42.39% | 47.54% |
Operating Margin | -17.14% | 14.10% | 10.37% | 10.63% | 12.12% |
Profit Margin | -14.02% | 9.53% | 7.59% | 7.68% | 10.61% |
Free Cash Flow Margin | -0.58% | 0.58% | -25.27% | 19.45% | -4.87% |
EBITDA | -57.21 | 131.52 | 91.49 | 73.94 | 79.64 |
EBITDA Margin | -11.41% | 17.12% | 14.85% | 17.00% | 20.15% |
D&A For EBITDA | 28.72 | 23.21 | 27.58 | 27.72 | 31.76 |
EBIT | -85.93 | 108.31 | 63.91 | 46.22 | 47.88 |
EBIT Margin | -17.14% | 14.10% | 10.37% | 10.63% | 12.12% |
Effective Tax Rate | - | 23.50% | 19.88% | 20.17% | 19.46% |